Privia Health Group, Inc. (NASDAQ:PRVA – Get Free Report) CEO Parth Mehrotra sold 15,647 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $22.64, for a total transaction of $354,248.08. Following the completion of the sale, the chief executive officer owned 434,357 shares in the company, valued at $9,833,842.48. This represents a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Parth Mehrotra also recently made the following trade(s):
- On Monday, May 11th, Parth Mehrotra sold 105,439 shares of Privia Health Group stock. The stock was sold at an average price of $22.55, for a total transaction of $2,377,649.45.
- On Monday, March 16th, Parth Mehrotra sold 26,509 shares of Privia Health Group stock. The stock was sold at an average price of $22.11, for a total transaction of $586,113.99.
- On Friday, March 13th, Parth Mehrotra sold 27,229 shares of Privia Health Group stock. The stock was sold at an average price of $21.52, for a total transaction of $585,968.08.
- On Thursday, March 12th, Parth Mehrotra sold 26,763 shares of Privia Health Group stock. The stock was sold at an average price of $21.90, for a total transaction of $586,109.70.
- On Tuesday, March 10th, Parth Mehrotra sold 21,097 shares of Privia Health Group stock. The stock was sold at an average price of $22.71, for a total transaction of $479,112.87.
- On Monday, March 9th, Parth Mehrotra sold 41,999 shares of Privia Health Group stock. The stock was sold at an average price of $22.86, for a total transaction of $960,097.14.
- On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The stock was sold at an average price of $23.15, for a total transaction of $496,336.00.
Privia Health Group Stock Performance
Shares of NASDAQ:PRVA traded down $0.38 during midday trading on Wednesday, reaching $22.63. 1,007,566 shares of the company’s stock were exchanged, compared to its average volume of 1,024,863. The company’s 50 day simple moving average is $22.65 and its two-hundred day simple moving average is $23.25. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $26.51. The firm has a market capitalization of $2.85 billion, a PE ratio of 141.45, a price-to-earnings-growth ratio of 1.69 and a beta of 0.96.
Hedge Funds Weigh In On Privia Health Group
Institutional investors have recently added to or reduced their stakes in the company. Great Lakes Advisors LLC bought a new position in Privia Health Group during the 3rd quarter valued at about $4,487,000. ArrowMark Colorado Holdings LLC bought a new position in shares of Privia Health Group in the third quarter worth about $8,750,000. Royce & Associates LP raised its stake in shares of Privia Health Group by 54.5% in the third quarter. Royce & Associates LP now owns 607,191 shares of the company’s stock worth $15,119,000 after acquiring an additional 214,166 shares during the last quarter. Public Sector Pension Investment Board raised its stake in shares of Privia Health Group by 25.9% in the third quarter. Public Sector Pension Investment Board now owns 450,010 shares of the company’s stock worth $11,205,000 after acquiring an additional 92,507 shares during the last quarter. Finally, Summit Global Investments raised its stake in shares of Privia Health Group by 273.9% in the third quarter. Summit Global Investments now owns 33,677 shares of the company’s stock worth $839,000 after acquiring an additional 24,670 shares during the last quarter. 94.48% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several brokerages have recently weighed in on PRVA. Evercore set a $26.00 target price on shares of Privia Health Group in a research report on Wednesday, April 8th. Citigroup decreased their target price on shares of Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Canaccord Genuity Group decreased their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Jefferies Financial Group reiterated a “buy” rating and set a $32.00 target price on shares of Privia Health Group in a research report on Thursday, February 26th. Finally, Barclays lifted their target price on shares of Privia Health Group from $23.00 to $25.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 25th. Eleven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Privia Health Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.23.
Check Out Our Latest Stock Report on Privia Health Group
Privia Health Group Company Profile
Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.
Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.
Read More
- Five stocks we like better than Privia Health Group
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
